# Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study

> **NCT05430854** · PHASE2 · TERMINATED · sponsor: **Amgen** · enrollment: 155 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** Daxdilimab

## Key facts

- **NCT ID:** NCT05430854
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-01
- **Primary completion:** 2023-10-31
- **Final completion:** 2023-10-31
- **Target enrollment:** 155 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05430854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05430854, "Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05430854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*